https://imedsciences.com/ editor_ijims@hotmail.com
ISSN: 2394-4137 (E) 2394-6318 (P)

IJIMS.2017.117

Type of Article: Original Research

Volume 5; Issue 3: 2018

Page No.: 583-586

DOI: 10.16965/ijims.2017.117

 

ROLE OF MYO-INOSITOL IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME

Madhavi. G.B. 1, Shamili. G *2, Ramadevi. E 3, Jyothi 4.

1 Professor in Department Of Obstetrics and Gynaecology ,Chalmeda Anand Rao Institute Of Medical Sciences, Karimnagar, Telangana, India.

*2 Post Graduate Student in Department Of Obstetrics and Gynaecology ,Chalmeda Anand Rao Institute of Medical Sciences, Karimnagar, Telangana, India.

3 Professor and HOD in Department Of Obstetrics and Gynaecology ,Chalmeda Anand Rao Institute Of Medical Sciences, Karimnagar, Telangana, India.

4 Assistant Professor in Department Of Obstetrics and Gynaecology ,Chalmeda Anand Rao Institute Of Medical Sciences, Karimnagar, Telangana, India.

Address for Correspondence: Dr. Shamili, Post Graduate, Department Of Obstetrics and Gynaecology, Chalmeda Anand Rao Institute Of Medical Sciences, Karimnagar-505001, Telangana, India. E-Mail: shamili.1025@gmail.com

ABSTRACT:

Background: Polycystic ovary syndrome (PCOS) is often characterized by chronic oligo- or anovulation (usually manifested as oligo- or amenorrhea), and hyperandrogenism. 30–40% of PCOS women have impaired glucose tolerance, and a defect in the insulin signaling pathway (inositol-containing phosphoglycan mediators) seems to be implicated in the pathogenesis of insulin resistance. PCOS patients are subfertile as a consequence of such ovulatory disorders and often need drugs, such as clomiphene citrate or follicle-stimulating hormone, for ovulation induction, which increases the risk of multiple pregnancy and ovarian hyperstimulation syndrome. We hypothesized that the administration of an isoform of inositol (myo-inositol), belonging to the vitamin B complex, would improve the insulin-receptor activity, restoring normal ovulatory function.

Materials and Methods: Twenty-five PCOS women of childbearing age with oligo- or amenorrhea were enrolled in the study. Ovulatory disorder due to PCOS was apparently the only cause of infertility; no tubal defect or deficiency of male semen parameters was found. Myo-inositol combined with folic acid (Inofolic1) 2 g twice a day was administered continuously. During an observation period of 6 months, ovulatory activity was monitored with ultrasound scan and hormonal profile, and the number of spontaneous menstrual cycles and eventually pregnancies were assessed.

Results: Twenty-two out of the 25 (88%) patients restored at least one spontaneous menstrual cycle during treatment, of whom 18 (72%) maintained normal ovulatory activity during the follow-up period. A total of 10 singleton pregnancies (40% of patients) were obtained. Nine clinical pregnancies were assessed with fetal heart beat at ultrasound scan. Two pregnancies evolved in spontaneous abortion.

Conclusion: Myo-inositol is a simple and safe treatment that is capable of restoring spontaneous ovarian activity and consequently fertility in most patients with PCOS. This therapy did not cause multiple pregnancy.

Key words: Myo-Inositol, Polycystic Ovary Syndrome, Ovulation Induction.

REFERENCES

  1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–1236.
  2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–861.
  3. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.
  4. Baillargeon JP, Nestler JE. Polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 2006;91:22–24.
  5. Larner J. Multiple pathways in insulin signaling – fitting the covalent and allosteric puzzle pieces together. Endocr J 1994;2:167–171.
  6. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE. Altered D-chiroinositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300–305.
  7. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effect of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–423.
  8. Yoshida K, Yamaguchi M, Morinaga T, Ikeuchi M, Kinehara M, Ashida H. Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigation drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. Appl Environ Microbiol 2006;72:1310–1315.
  9. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Human Reprod 2002;17:1591–1596.
  10. Chiu TT, Rogers MS, Briton-Jones C, Haines C. Effect of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Human Reprod 2003;18: 408–416.
  11. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005;84: 611–616.
  12. Battaglia C, Mancini F, Persico N, Zaccaria V, de Aloysio D. Ultrasound evaluation of PCO, PCOS and OHSS. Reprod Biomed Online 2004;9:614–619.
  13. Cheang KI, Nestler JE. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online 2004;8:440–447.
  14. Baillargeon JP. Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Investig Drugs 2005;6:1012– 1022.
  15. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, et al.; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551–566.
  16. Pesant MH, Baillargeon JP. Ovulation induction in polycystic ovary syndrome – how do metformin and clomifene citrate compare? Nat Clin Pract Endocr Metab 2007;3:512–513.
  17. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. B Med J 2003;327:951–957.
  18. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314– 1320.
  19. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003;7:151–159.
Download Full Text TOC